Rchr
J-GLOBAL ID：201801020468534176
Update date: Nov. 18, 2024
Narikazu Boku
ボク ナリカズ | Narikazu Boku
Affiliation and department：
Job title：
Professor
Research field (1)：
Tumor diagnostics and therapeutics
Research theme for competitive and other funds (5)：
- 2020 - 2023 Elucidation of cancer diversity mechanism by analysis of phosphorylation signal using biopsy tissue and application to precision medicine
- 2015 - 2018 Research on new related diseases and conditions of diabetes mellitus using a large-scale database of medical claims data and data from health checkups
- 2014 - 2017 Functional analysis of BRCA1 as the molecular basis of breast cancer therapy
- 2012 - 2015 Cancer therapeutic target identification by comprehensive kinase profiling
- 2011 - 2014 Research on the breast cancer chemotherapy targeting synthetic lethality caused by the factors in the DNA damage repair pathways.
Papers (406)：
-
Hirokazu Shoji, Chie Kudo-Saito, Kengo Nagashima, Hiroshi Imazeki, Kai Tsugaru, Naoki Takahashi, Takeshi Kawakami, Yusuke Amanuma, Takeru Wakatsuki, Naohiro Okano, et al. Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study). Journal for immunotherapy of cancer. 2024. 12. 11
-
Toshifumi Yamaguchi, Koshi Kumagai, Shusuke Yagi, Takashi Nomura, Kengo Nagashima, Masaya Watanabe, Rie Makuuchi, Kentaro Kawakami, Tomohiro Matsushima, Shigenori Kadowaki, et al. Efficacy of chemotherapy for patients with gastric cancer with early recurrence during or after adjuvant chemotherapy with S-1 alone: a multicenter retrospective study. Scientific Reports. 2024. 14. 1
-
Tomohiro Nishina, Narikazu Boku, Yukinori Kurokawa, Keita Sasaki, Ryunosuke Machida, Takaki Yoshikawa. A real-world survey on expensive drugs used as first-line chemotherapy in patients with HER2-negative unresectable advanced/recurrent gastric cancer in the stomach cancer study group of the Japan clinical oncology group. Japanese Journal of Clinical Oncology. 2024
-
Koshiro Fukuda, Hiroki Osumi, Yuri Yoshinami, Akira Ooki, Atsuo Takashima, Takeru Wakatsuki, Hidekazu Hirano, Izuma Nakayama, Kota Ouchi, Ryoichi Sawada, et al. Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study. Journal of cancer research and clinical oncology. 2024. 150. 7. 369-369
-
門田 智裕, 蓮池 典明, 小野 裕之, 朴 成和, 水澤 純基, 小田 一郎, 小山 恒男, 堀内 裕介, 平澤 欣吾, 由雄 敏之, et al. 分化型早期胃癌ESD適応拡大病変におけるESD後非治癒切除因子の検討(JCOG0607副次的解析). Gastroenterological Endoscopy. 2024. 66. 6. 1366-1376
ｍore...
MISC (219)：
-
石橋 正祥, 飯村 洋平, 古川 直樹, 流石 智恵子, 馬場 啓介, 朴 成和, 黒田 誠一郎. 大腸癌術後補助化学療法のCapeOx療法における血管痛発現要因の解析. 日本臨床腫瘍薬学会雑誌. 2023. 30. 261-261
-
堀内 裕介, 滝沢 耕平, 由雄 敏之, 吉田 尚弘, 矢野 友規, 三輪 洋人, 蓮池 典明, 小野 裕之, 武藤 学, 水澤 純基, et al. 未分化型成分を有する早期胃癌に対する内視鏡的粘膜下層剥離術後にeCuraC-2となる例の特徴 当グループ試験事後解析. Gastroenterological Endoscopy. 2021. 63. Suppl.2. 2059-2059
-
山口 和也, 吉田 和弘, 李 相雄, 加治 正英, 櫻本 信一, 水澤 純基, 福田 治彦, 朴 成和, 吉川 貴己, 寺島 雅典. 高齢者胃癌に対する治療の工夫 高齢者に対する病理学的Stage II/III胃癌の術後補助化学療法に関する臨床試験(JCOG1507). 日本消化器外科学会総会. 2021. 76回. WS10-1
-
山口 和也, 吉田 和弘, 李 相雄, 加治 正英, 櫻本 信一, 水澤 純基, 福田 治彦, 朴 成和, 吉川 貴己, 寺島 雅典. 高齢者胃癌に対する治療の工夫 高齢者に対する病理学的Stage II/III胃癌の術後補助化学療法に関する臨床試験(JCOG1507). 日本消化器外科学会総会. 2021. 76回. WS10-1
-
Masahiko Aoki, Satoru Iwasa, Narikazu Boku. Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective. Gastric Cancer. 2021. 24. 3. 567-576
ｍore...
Lectures and oral presentations (10)：
-
7. Randomizedphase II/III study of FLvs. FLTAX in gastric cancer with severe peritoneal metastasis (JCOG1108/WJOG7312G
(2019)
-
6. Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel in gastric cancer with severe peritoneal metastasis (JCOG1108/WJOG7312G
(ASCO-GI 2019)
-
5. CT image features of peritoneal metastasis and outcomes of the advanced gastric cancer patients receiving 2nd line chemotherapy
(ESMO-Asia 2018)
-
4. Impact of adding ramucirumab to paclitaxel in patients with advanced gastric cancer according to the level of ascites
(2018)
-
3. Impact of ascites on the treatment of nivolumab for advanced gastric cancer patients
(2018)
ｍore...
Professional career (1)：
Return to Previous Page
